BC Innovations | Feb 14, 2018
Distillery Therapeutics

Cardiovascular

INDICATION: Aneurysm Mouse studies suggest the CysLT1 inhibitor Singulair montelukast could help treat abdominal aortic aneurysm (AAA). In a mouse model of calcium chloride-induced AAA, Singulair decreased aortic dilation compared with no treatment. In a...
BC Week In Review | Sep 12, 2016
Company News

Kyorin sales and marketing update

Kyorin launched montelukast in Japan to treat bronchial asthma and allergic rhinitis. Montelukast is a generic of Kipres, which Kyorin markets in Japan. The National Health Insurance (NHI) list price of generic montelukast is Y101.80...
BC Week In Review | Sep 5, 2016
Clinical News

Montelukast VersaFilm: Phase I data

Top-line data from an open-label, crossover Phase I trial in 8 healthy volunteers showed that the bioavailability of montelukast following a single dose of Montelukast VersaFilm was 52% greater compared to Singulair montelukast tablets. IntelGenx...
BC Week In Review | Jul 25, 2016
Clinical News

Montelukast VersaFilm: Phase I started

IntelGenx began an open-label Phase I trial to compare montelukast VersaFilm vs. Singulair montelukast in healthy volunteers. IntelGenx plans to repurpose the drug for degenerative diseases of the brain, such as mild cognitive impairment (MCI)...
BC Innovations | Jan 7, 2016
Distillery Therapeutics

Therapeutics: Leukotriene C4 (LTC4); cysteinyl leukotriene receptor 2 (CYSLTR2; CysLT2); CysLT1

Other INDICATION: Poisoning Cell culture and mouse studies suggest inhibiting LTC4 or its receptors, CysLT1 and CYSLTR2 , could help treat chemotherapy-related toxicity. In a HeLa-derived cell line, the generic chemotherapies doxorubicin and 5-fluorouracil (5-FU) increased...
BC Week In Review | Aug 24, 2015
Clinical News

Montelukast sodium regulatory update

Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569), Tokyo, Japan   Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J.   Product: Montelukast sodium ( Kipres OD Tablets )   Business: Inflammation   Kyorin said Japan approved Kipres OD Tablets, an orally...
BioCentury | Nov 19, 2012
Strategy

Celgene's venture model

Although it has eschewed creating a corporate venture arm, Celgene Corp. has been an active investor in private biotechs for at least the last five years, tapping a network of scientists and VCs to identify...
BC Week In Review | May 16, 2011
Clinical News

Accolate zafirlukast inflammation data

Researchers from the University of Aberdeen reported data from 2 open-label pragmatic trials showing that leukotriene antagonists Singular and Accolate produced equivalent increases in MiniAQLQ scores vs. inhaled corticosteroid controller medication (ICS) as first-line therapy...
BC Week In Review | Sep 8, 2008
Clinical News

Singulair montelukast inflammation data

An independent analysis of data from the double-blind LODO, TAPE and LOCCS trials was published in the Journal of Allergy and Clinical Immunology and showed that Singulair montelukast had a positive effect on emotional outlook...
BC Week In Review | Sep 8, 2008
Clinical News

Singulair montelukast: Phase IV data

An independent analysis of data from the double-blind LODO, TAPE and LOCCS trials was published in the Journal of Allergy and Clinical Immunology and showed that Singulair montelukast had a positive effect on emotional outlook...
Items per page:
1 - 10 of 21